Marilesia Ferreira de Souza

Marilesia Ferreira de Souza

Auto-generated profile, based on publicly available information

Marilesia Ferreira de Souza

Department of General Biology, State University of Londrina, Londrina 86057-970, PR, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
MSMarilesia Ferreira Souza
Marilesia Ferreira Souza
ICIlce Mara Syllos Colus
Ilce Mara Syllos Colus
AFAline Simoneti Fonseca
Aline Simoneti Fonseca
VAValquíria Casanova Antunes
Valquíria Casanova Antunes
DKDeepak Kumar
Deepak Kumar
LCLuciane Cavalli
Luciane Cavalli
Prostate cancer (PCa) is a clinically heterogeneous disease, where deregulation of epigenetic events, such as miRNA expression alterations, are determinants for its development and progression. MiR-182-5p, a member of the miR-183 family, when overexpressed has been associated with PCa tumor progression and decreased patients’ survival rates. In this study, we determined the regulatory role of miR-182-5p in modulating aggressive tumor phenotypes in androgen-refractory PCa cell lines (PC3 and DU-145). The transient transfection of the cell lines with miR-182-5p inhibitor and mimic systems, significantly affected cell proliferation, adhesion, migration, and the viability of the cells to the chemotherapeutic agents, docetaxel, and abiraterone. It also affected the protein expression levels of the tumor progression marker pAKT. These changes, however, were differentially observed in the cell lines studied. A comprehensive biological and functional enrichment analysis and miRNA/mRNA interaction revealed its strong involvement in the epithelial-mesenchymal transition (EMT) process; expression analysis of EMT markers in the PCa transfected cells directly or indirectly modulated the analyzed tumor phenotypes. In conclusion, miR-182-5p differentially impacts tumorigenesis in androgen-refractory PCa cells, in a compatible oncomiR mode of action by targeting EMT-associated pathways.

4 August 2022 in Journal of Cancer Research and Clinical Oncology
Verified
Journal Article
Closed access
PDF file
MNMonyse de Nóbrega
Monyse de Nóbrega
MRMariana Bisarro dos Reis
Mariana Bisarro dos Reis
ÉPÉrica Romão Pereira
Érica Romão Pereira
MSMarilesia Ferreira de Souza
Marilesia Ferreira de Souza
ICIlce Mara Syllos Colus
Ilce Mara Syllos Colus

1 January 2020 in Genetics and Molecular Biology
Verified
Journal Article
Open access
PDF file
MNMonyse De Nóbrega
Monyse De Nóbrega
HCHeloisa Lizotti Cilião
Heloisa Lizotti Cilião
MSMarilesia Ferreira De Souza
Marilesia Ferreira De Souza
MSMilene Roldão De Souza
Milene Roldão De Souza
Juliana Mara SerpeloniJuliana Mara Serpeloni
Juliana Mara Serpeloni
ICIlce Mara Syllos Colus
Ilce Mara Syllos Colus
Polymorphic variants in the PTEN (rs2735343), PI3K (rs2699887), AKT1 (rs2494750), AR (rs17302090), and AMACR (rs3195676) genes were evaluated as possible molecular markers of susceptibility, prognosis, and progression of prostate cancer (PCa), in a case-control study. Samples consisted of 277 patients with PCa and 277 controls from Londrina, PR, Brazil. SNPs were analyzed by real-time PCR. A family history of cancer, including PCa, as well as level of schooling were risk factors for PCa. The data were obtained via logistic regression, using odds ratios with a CI 95%. The genotypes of AKT1 and AKT1+AR demonstrated an association with protection for the disease. The combination of SNPs with the histopathological tumor data between allele variants of AMACR, AKT1+AR, and AKT1+AMACR indicated an association with protection against seminal vesicle invasion. The polymorphisms AKT1+AR and PI3K+AR were associated with protection against tumor bilaterality. The genotype combinations PTEN+AMACR and PTEN+AR were associated with the risk of extracapsular extension. Of the five genes studied, two were associated with protection for PCa, four were associated with protection for some prognostic variables, and only one was associated with risk. Thus, these SNPs are candidates for markers to discriminate men with better or worse prognosis for PCa.

16 June 2022 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
MSMarilesia Ferreira de Souza
Marilesia Ferreira de Souza
MNMonyse de Nóbrega
Monyse de Nóbrega
HCHeloísa Lizotti Cilião
Heloísa Lizotti Cilião
MRMariana Bisarro dos Reis
Mariana Bisarro dos Reis
PFPaulo Emílio Fuganti
Paulo Emílio Fuganti
ICIlce Mara Syllos Colus
Ilce Mara Syllos Colus

30 August 2026 in Non-Coding RNA
Verified
Journal Article
Open access
PDF file
MNMonyse Nobrega
Monyse Nobrega
HKHellen Kuasne
Hellen Kuasne
MSMarilesia Ferreira de Souza
Marilesia Ferreira de Souza
MRMariana Bisarro dos Reis
Mariana Bisarro dos Reis
LOLarissa Cristina Bastos de Oliveira
Larissa Cristina Bastos de Oliveira
ICIlce Mara Syllos Colus
Ilce Mara Syllos Colus
Background/Objectives: Prostate cancer (PCa) has a high incidence worldwide, yet reliable prognostic biomarkers to distinguish indolent from aggressive forms are lacking. MicroRNAs (miRNAs), a class of small non-coding RNAs, are stable molecules that play an important role in cancer development and can be detected in circulation by non-invasive methods. This study aimed to examine the influence of the cell-free (cf) miRNAs levels on PCa risk and aggressiveness using plasma samples and cell models. Methods: Four overexpressed miRNAs in prostate cancer tissue were selected from The Cancer Genome Atlas database: miR-25-3p, miR-92a-1-5p, miR-92a-2-5p, and miR-148a-3p. Cf-miRNA levels were validated via quantitative reverse transcription polymerase chain reaction (RT-qPCR) in plasma samples from 80 PCa patients and 40 controls in a Brazilian cohort. Clinicopathological associations were analyzed to determine prognostic value. Subsequently, functional analyses were performed using transient transfection of miR-25-3p in the LNCaP cell line, assessing proliferation, migration, invasion, and target gene regulation. Results: Among the miRNAs analyzed, only miR-25-3p was upregulated in the plasma of PCa patients compared to controls (p = 0.013). Patients with International Society of Urological Pathology (ISUP) grade ≥2 presented higher expression levels of miR-25-3p (p = 0.020) compared to patients with ISUP grade 1. Overexpression of miR-25-3p significantly increased cell proliferation, colony formation, migration, and invasion capacity and modulated the expression of BCL2L11, CDH1, CDKN1C, EHZ2, and TP53 genes. Conclusions: miR-25-3p had an oncogenic role in PCa, showing a potential marker to assess PCa development and progression using liquid biopsy.

18 December 2024 in Gene
Verified
Journal Article
Closed access
Juliana Mara SerpeloniJuliana Mara Serpeloni
Juliana Mara Serpeloni
ISIsabely Mayara da Silva
Isabely Mayara da Silva
ALAndre van Helvoort Lengert
Andre van Helvoort Lengert
MSMarilesia Ferreira de Souza
Marilesia Ferreira de Souza
MRMariana Bisarro dos Reis
Mariana Bisarro dos Reis
ICIlce Mara Syllos Colus
Ilce Mara Syllos Colus